Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-09

Study Completion Date

2019-06-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-831 when administered as single or multiple oral doses in healthy adult Asian participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Participants

NCT04461483

Healthy Volunteer

COMPLETED PHASE1

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants

NCT03224325

Healthy

COMPLETED PHASE1

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

NCT02706834

Dose Finding Study

COMPLETED PHASE1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

NCT03933488

Healthy Participants

COMPLETED PHASE1

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants

NCT03237156

Japanese Healthy Adult Male Participants

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The drug being tested in this study is called TAK-831. This study will assess the safety, tolerability, pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-831 when administered as single or multiple oral doses in healthy adult Asian participants (Japanese and Chinese participants).

The study will enroll approximately 40 participants and include up to 5 cohorts of healthy adult Japanese or Chinese participants as following (8 participants per a cohort). Cohorts 3, 4 and 5 are optional and will be decided to run based on the data of Cohorts 1 and 2. Dose level for these cohorts will be defined based on the result of Cohort 1 or Cohort 2.

* Japanese Cohort 1-A; TAK-831 100 mg single dose + TAK-831 300 mg single dose
* Japanese Cohort 1-B; TAK-831 100 mg single dose + Placebo single dose
* Japanese Cohort 1-C; Placebo single dose + TAK-831 300 mg single dose
* Japanese Cohort 2; TAK-831 300 mg or TAK-831 matching placebo, single dose + TAK-831 300 mg or TAK-831 matching placebo, multiple dose \*
* Chinese Cohort 3; TAK-831 600 mg or TAK-831 matching placebo, single dose + TAK-831 600 mg or TAK-831 matching placebo, multiple dose
* Japanese Cohort 4; TAK-831 600 mg or TAK-831 matching placebo, single dose + TAK-831 600 mg or TAK-831 matching placebo, multiple dose
* Japanese Cohort 5; TAK-831 50 mg or TAK-831 matching placebo, single dose + TAK-831 50 mg or TAK-831 matching placebo, multiple dose \*The dose in Cohort 2 will be adjusted based on the safety and tolerability as well as PK and PD in Cohort 1.

Above all treatment, randomization information will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need) and TAK-831 will be administered orally.

This single center trial will be conducted in Japan. The overall time to participate in Cohort 1 of this study is approximately 12 days and 19 days in Cohorts 2 to 5. 11 days (for Cohort 1) or 12 days (for Cohorts 2 to 5) after last dose of study drug, participants will be contacted by telephone for a follow-up assessment unless abnormal, clinically significant findings are observed upon discharge.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Japanese Cohort 1-A; TAK-831 100 mg + TAK-831 300 mg

TAK-831 100 milligrams (mg), tablets, orally, once daily on Day 1, followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.

Group Type EXPERIMENTAL

TAK-831

Intervention Type DRUG

TAK-831 Tablets.

Japanese Cohort 1-B; TAK-831 100 mg + Placebo

TAK-831 100 mg, tablets, orally, once daily on Day 1 followed by TAK-831 matching placebo, tablets, orally, once daily on Day 9 in healthy Japanese participants.

Group Type EXPERIMENTAL

TAK-831

Intervention Type DRUG

TAK-831 Tablets.

Placebo

Intervention Type DRUG

TAK-831 Matching Placebo Tablets.

Japanese Cohort 1-C; Placebo + TAK-831 300 mg

TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.

Group Type EXPERIMENTAL

TAK-831

Intervention Type DRUG

TAK-831 Tablets.

Placebo

Intervention Type DRUG

TAK-831 Matching Placebo Tablets.

Japanese Cohort 2; TAK-831 300 mg

TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.

Group Type EXPERIMENTAL

TAK-831

Intervention Type DRUG

TAK-831 Tablets.

Placebo

Intervention Type DRUG

TAK-831 Matching Placebo Tablets.

Chinese Cohort 3; TAK-831 600 mg

TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Chinese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.

Group Type EXPERIMENTAL

TAK-831

Intervention Type DRUG

TAK-831 Tablets.

Placebo

Intervention Type DRUG

TAK-831 Matching Placebo Tablets.

Japanese Cohort 4; TAK-831 600 mg

TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.

Group Type EXPERIMENTAL

TAK-831

Intervention Type DRUG

TAK-831 Tablets.

Placebo

Intervention Type DRUG

TAK-831 Matching Placebo Tablets.

Japanese Cohort 5; TAK-831

TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.

Group Type EXPERIMENTAL

TAK-831

Intervention Type DRUG

TAK-831 Tablets.

Placebo

Intervention Type DRUG

TAK-831 Matching Placebo Tablets.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TAK-831

TAK-831 Tablets.

Intervention Type DRUG

Placebo

TAK-831 Matching Placebo Tablets.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The participant must understand the study procedures and agree to participate by providing written informed consent (for Chinese participants, an interpreter should be present as necessary).
2. The participant must be willing and able to comply with all study procedures and restrictions.
3. The participant must be male or female (of nonchildbearing potential) aged 20 to 55 years, inclusive, at the Screening.
4. The participant must have a body mass index (BMI) \>=18.5 kg/m\^2 and =\<25.0 kg/m\^2 at the Screening.
5. The participant must be a current nonsmoker who has not used tobacco- or nicotine-containing products (e.g., nicotine patch) for at least 6 months prior to the Screening.
6. Chinese participants are defined as participants who were born in mainland China, and their biological parents and grandparents must all have been of Chinese origin (for Cohort 3 only).
7. Chinese participants who have lived out of China for more than 5 years must not have significantly modified their diets since leaving China (for Cohort 3 only).
8. The participant must be judged to be in good health by the investigator, based on clinical evaluations including laboratory tests, medical history, full physical examination, 12-lead electrocardiogram, and vital sign measurements performed at the Screening and prior to the first dose of study drug.
9. The participant must meet the birth control requirements.

Exclusion Criteria

1. The participant has a history of clinically significant endocrine, gastrointestinal (including motility disorder and intestinal obstruction), cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary, or presents with major neurological (including stroke and chronic seizures) abnormalities or diseases.
2. The participant has participated in another investigational trial within 4 weeks before the pretrial visit (Screening). The 4-week window will be derived from the date of the last trial procedure and/or adverse event (AE) related to the trial procedure in the previous trial to the Screening Visit of the current trial.
3. The participant is an employee or immediate family member (e.g., spouse, parent, child, sibling) of the sponsor.
4. The participant has a history of cancer (malignancy).
5. The participant has a history of significant multiple and/or severe allergies (e.g., food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food.
6. The participant has a positive alcohol or drug or immunological screen.
7. The participant is of childbearing potential or lactating.
8. The participant had major surgery, received or lost 1 unit of blood (approximately 500 milliliters \[mL\]) within 8 weeks prior to the first dose of study drug.
9. The participant with any gastrointestinal (GI) surgery that could impact upon the absorption of study drug.
10. The participant has a known hypersensitivity to any component of the formulation of TAK-831 or related compounds.
11. The participant is unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs or herbal remedies, beginning approximately 7 days before administration of the initial dose of trial drug, throughout the trial (including washout intervals between trial periods), until the Follow-up Visit.
12. The participant has a history of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to: beer \[354 mL/12 ounces\], wine \[118 mL/4 ounces\], or distilled spirits \[29.5 mL/1 ounce\] per day).
13. The participant who consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.
14. The participant has a history of drug abuse.
15. The participant has a (QT interval with Fridericia's correction method) QTcF \>450 milliseconds (msec) (males) or \>470 msec (females) or PR outside the range of 120 to 220 msec at the Screening Visit or Check-in.

Minimum Eligible Age

20 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes